Company Overview and News

DigitalX teams with MailGuard to develop blockchain based cybersecurity network

DigitalX Ltd (ASX:DCC) has been appointed corporate advisor to MailGuard, the world’s largest private Software as a Service (SaaS) email security company.
Upvote Downvote

ShareRoot targeting multi-billion industry with roll-out of MediaConsent platform

ShareRoot Ltd (ASX:SRO) will look to complement its existing platform with the roll-out of the MediaConsent platform this quarter.
Upvote Downvote

Shareroot's engagement of blockchain advisor enhances security of content platform

Shareroot Ltd (ASX:SRO) has appointed blockchain and digital advisory company, DigitalX Limited (ASX:DCC) as the group’s blockchain advisor, a security enhancing initiative.
Upvote Downvote

First Growth Funds to seek Blockchain investments

First Growth Funds Ltd (ASX:FGF) intends using the majority of funds from a $3.45 million placement to seek Blockchain related investment opportunities.
Upvote Downvote

DigitalX’s client Bankera closes €25M pre-initial coin offering

DigitalX Ltd’s (ASX:DCC) client Bankera has successfully closed its €25 million pre-initial coin offering (ICO) via the sale of 2.5 billion “Bankers” (BNK) tokens at €0.01 each.
Upvote Downvote

DigitalX to reveal strategic investment

DigitalX (ASX:DCC) has been granted a trading halt by the ASX, pending details of a strategic investment.
Upvote Downvote

DigitalX is focused on disrupting the payments industry

DigitalX (ASX:DCC) has been granted a trading halt by the ASX, pending the completion of the issue of tranche 1 of the convertible notes announced earlier in the week.
Upvote Downvote

DigitalX to provide update from Latin America

DigitalX (ASX:DCC) has been granted a trading halt by the ASX, with its shares placed in pre-open.
Upvote Downvote

DigitalX to launch money transfer feature for its app in the U.S.

DigitalX (ASX:DCC) is set to launch the money transfer feature for its AirPocket app this week in the U.S., incorporating the ability to make low-cost international money transfers.
Upvote Downvote

DigitalX to reveal corporate transaction

DigitalX (ASX:DCC) has been granted a trading halt by the ASX in order to finalise a proposed corporate divestment transaction.
Upvote Downvote

DigitalX Ltd gets ready to raise

DigitalX Ltd (ASX:DCC) is heading to market with a capital raising. The ASX has granted the company a trading halt, with its shares placed in pre-open. The halt will remain in place until the opening of trade on Tuesday 6th September 2016, or earlier if an announcement is made to the market.
Upvote Downvote

DigitalX Ltd to reveal transaction

DigitalX Ltd (ASX:DCC) has been granted a trading halt by the ASX this morning, pending details of a transaction relating to securities in the company. The halt will remain in place until the opening of trade on Thursday 25th August 2016, or earlier if an announcement is made to the market.
Upvote Downvote

DigitalX Ltd tests blockchain based app to send money overseas

DigitalX Ltd (ASX:DCC), a blockchain software solutions company is gaining positive feedback from the expanded phase 2 beta-test of its AirPocket money transfer app that was conducted in the U.S. and Dominican Republic. The Phase 2 trial allowed users to transfer money from nine selected states in the U.S. to the Dominican Republic. AirPocket utilises the Bitcoin blockchain technology to transfer money.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...